ESR1 and cancer: Since the amount of immune cell infiltrations in allograft score high in ER-positive/HER2-negative subtype were roughly same as allograft score low in TNBC, we cannot help but speculate that high allograft score in ER-positive/HER2-negative subtype do not have enough immune cell infiltration to outperform pro-cancer signaling.